How to Reduce Late Stage Attrition in Drug Discovery

This FREE webinar was recorded on:
10:00 AM - 11:00 AM EST

Sponsored By:

 At the upcoming Predictive Toxicology Academy,   Sheraz Gul will explore the topic of reducing late stage attrition in drug discovery. The interactive webinar will pause to examine lessons learnt from real world case studies as well as discussing topic of industry standard criteria for progressing R&D pharma projects. 

When: 10th November at 3pm GMT 

How: Register for this webinar using the button above and you will recieve instructions on how to attend this live webinar. 

About the Predictive Toxicology Academy:  Following a series of successful real world conferences, to aid worldwide accessibility the Predictive Toxicology Academy brings you an evolving hub of online resources all accessible from the comfort of your desk. This November, the Academy will grow to become a library hosting a portfolio of various multimedia including live interactive sessions, whitepapers, podcasts, infographics, articles and interviews. Each week will have a fresh topic of focus within predictive toxicology.

Register for updates for the Predictive Toxicology Academy here today. 

Have Your Say
Rate this feature and give us your feedback in the comments section below
Sheraz Gul Head of Assay Development & Screening Fraunhofer Institute for Molecular Biology and Applied Ecology – ScreeningPort.

Sheraz is Head of Assay Development & Screening at the Fraunhofer Institute for Molecular Biology and Applied Ecology – ScreeningPort. In his role, he is responsible for the management and development of Assay Development and Medium and High Throughput Screening activities for partners across the world. He has 23 years’ experience in both academia (University of London) and industry (GlaxoSmithKline Pharmaceuticals). This has ranged from the detailed study of catalysis by biological catalysts (enzymes and catalytic antibodies) to the design and development of assays for High Throughput Screening for the major drug target classes. He is the co-author of numerous papers, chapters and the Enzyme Assays: Essential Data handbook.

He now works for the Fraunhofer Institute - one of the largest applied research organisations in Europe employing around 23,000 staff.